biospecimen banks

CPDR Patient Education Program

Helpful Resources

 

Agent Orange and Prostate Cancer

Veterans diagnosed with prostate cancer may qualify for service-connected disability compensation.
Information Sheet

 

Special Clinic at WRNMMC for Men with Prostate Cancer

The Center for Prostate Disease Research (CPDR) at Walter Reed National Military Medical Center (WRNMMC) has a special clinic for men diagnosed with prostate cancer called the "Multi-Disciplinary Prostate Cancer Clinic".
More Information

 

Patient Education Links

American Cancer Society
Website: Cancer.Org
Phone: 800-ACS-2345

National Cancer Institute
Website: Cancer.Gov
Phone: 800-4-CANCER

National Comprehensive Cancer Network
Website: www.nccn.com

Us TOO International Prostate Cancer Education and Support Network
Website: www.ustoo.org
Phone: 800-808-7866

American Urological Association
Website: www.urologyhealth.org
Phone: 800-828-7866

Prostate Cancer Research Institute
Website: www.prostate-cancer.org
Phne: 800-641-7274

 

Newsletters

Choices
Website: www.paactusa.org
Phone: 616-453-1477

PCRI Insights
Website: www.pcri.org
Phone: 310-743-2117

The John Hopkins Prostate Bulletin
Phone: 800-829-0422

Us TOO Hotsheets
Website: www.ustoo.org

WRNMMC Us TOO Newsletter
Website: cpdr.org
Phone: 301-319-2918

CURRENT EVENTS


September 29, 2014

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients

REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).

Read Full Article.

Read Publication - European Urology

 

WRNMMC UsToo!

Read the NOVEMEBR 2014 Newsletter